Clinical Trials Browser

Phase 4 × Lung Neoplasms × Erlotinib Hydrochloride × Clear all

NCT04145570 2019-10-30

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

Phase 4 Completed

Lung Neoplasms

NCT01320501 2016-05-13

REALME

Phase 4 Suspended

Lung Neoplasms

NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Phase 4 Completed

GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors